CA2348756A1 - Enhanced vaccines - Google Patents

Enhanced vaccines Download PDF

Info

Publication number
CA2348756A1
CA2348756A1 CA002348756A CA2348756A CA2348756A1 CA 2348756 A1 CA2348756 A1 CA 2348756A1 CA 002348756 A CA002348756 A CA 002348756A CA 2348756 A CA2348756 A CA 2348756A CA 2348756 A1 CA2348756 A1 CA 2348756A1
Authority
CA
Canada
Prior art keywords
polypeptide
complex
ige
mammal
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002348756A
Other languages
English (en)
French (fr)
Inventor
Lars T. Hellman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resistentia Pharmaceuticals AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2348756A1 publication Critical patent/CA2348756A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002348756A 1998-11-02 1999-10-21 Enhanced vaccines Abandoned CA2348756A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10665298P 1998-11-02 1998-11-02
US60/106,652 1998-11-02
US09/401,636 US6913749B2 (en) 1998-11-02 1999-09-22 Immunogenic polypeptides for inducing anti-self IgE responses
US09/401,636 1999-09-22
PCT/SE1999/001896 WO2000025722A2 (en) 1998-11-02 1999-10-21 ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS

Publications (1)

Publication Number Publication Date
CA2348756A1 true CA2348756A1 (en) 2000-05-11

Family

ID=26803871

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002348756A Abandoned CA2348756A1 (en) 1998-11-02 1999-10-21 Enhanced vaccines

Country Status (17)

Country Link
US (3) US6913749B2 (https=)
EP (1) EP1135158B1 (https=)
JP (2) JP4205861B2 (https=)
KR (1) KR100559918B1 (https=)
AT (1) ATE314087T1 (https=)
AU (1) AU771889B2 (https=)
CA (1) CA2348756A1 (https=)
DE (1) DE69929240T2 (https=)
DK (1) DK1135158T3 (https=)
ES (1) ES2255325T3 (https=)
HU (1) HUP0105392A3 (https=)
IL (1) IL142582A0 (https=)
NO (1) NO20012135L (https=)
NZ (1) NZ511079A (https=)
PL (1) PL348611A1 (https=)
PT (1) PT1135158E (https=)
WO (1) WO2000025722A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7658101A (en) * 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
EP2361635A3 (en) * 2000-08-30 2011-09-14 Pfizer Products Inc. Anti IgE vaccines
EP1330263A2 (en) * 2000-09-06 2003-07-30 Pharmexa A/S Method for down-regulating ige
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
EP2848255B1 (en) 2001-02-20 2017-08-23 Janssen Pharmaceuticals, Inc. Artificial Drosophila antigen presenting cell for preparing CD8 cell suspension for use in the treatment of cancer
ATE438710T1 (de) 2001-05-15 2009-08-15 Ortho Mcneil Janssen Pharm Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
WO2003096966A2 (en) * 2002-05-21 2003-11-27 Resistentia Pharmaceuticals Ab Chimeric ige polypeptides and host cells
ATE414540T1 (de) * 2002-09-05 2008-12-15 Resistentia Pharmaceuticals Ab Impfstoffe gegen allergien
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
US20100166804A1 (en) * 2007-05-23 2010-07-01 Dennis Penn Methods
WO2009142772A2 (en) * 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
KR101413844B1 (ko) 2008-12-09 2014-06-30 화이자 백신스 엘엘씨 ＩｇＥ ＣＨ３ 펩티드 백신
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
CN104395337A (zh) * 2012-06-18 2015-03-04 日本全药工业株式会社 IgE肽疫苗
AU2017221425A1 (en) 2016-02-16 2018-08-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
EP4582442A3 (en) 2019-06-24 2025-10-29 Universität Stuttgart Tnfr2 agonists with improved stability

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US5698201A (en) 1973-05-07 1997-12-16 The Ohio State University Method for treatment of antigenically modified polypeptides
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4483793A (en) 1982-10-04 1984-11-20 The Regents Of The University Of California Dimeric oligopeptides as heptenic epitopic sites for hepatitis
US4782137A (en) 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5175385A (en) 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
GB8727045D0 (en) 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
WO1989006138A1 (en) 1987-12-31 1989-07-13 Tanox Biosystems, Inc. UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8910263D0 (en) 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5955076A (en) * 1989-06-15 1999-09-21 Peptide Therapeutics Limited Immunoactive peptides and antibodies and their use in anti-allergy treatment
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
US5733553A (en) 1989-09-29 1998-03-31 Talwar; Gursaran Prasad Recombinant birth control vaccine
SG70982A1 (en) 1990-01-23 2000-03-21 Tanox Biosystems Inc Extracellular segments of human and immunoglobulin anchoring peptides and antibodies specific therefor
EP0605410B1 (en) * 1990-05-25 1995-08-16 Peptide Therapeutics Limited Immunodiagnostic assay for rheumatoid arthritis
US5196197A (en) 1990-08-29 1993-03-23 National Institute Of Immunology Reversible fertility control for prevention of pregnancy in females
CA2097291A1 (en) * 1990-12-13 1992-06-14 David P. Gearing Leukemia inhibitory factor receptors
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
US5837686A (en) * 1991-11-25 1998-11-17 Peptide Therapeutics Limited Peptides and antibodies for treatment of rheumatoid arthritis
EP0662085A1 (en) 1992-09-01 1995-07-12 International Centre for Genetic Engineering and Biotechnology Peptide showing cross-reactivity with the anti-hepatitis b surface antigen antiserum
AU5361794A (en) 1992-10-14 1994-05-09 Board Of Trustees Of The Leland Stanford Junior University Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates
US5762931A (en) 1992-12-31 1998-06-09 National Institute Of Immunology Anti-cancer utility of HCG vaccines
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
US5552537A (en) * 1993-03-24 1996-09-03 The Regents Of The University Of California IgE isoforms and methods of use
US5501855A (en) 1993-09-02 1996-03-26 Talwar; Gursaran P. Neem oil as a male contraceptive
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
FR2715304B1 (fr) 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
EP0811016A1 (en) 1994-03-28 1997-12-10 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
CN1167491A (zh) 1994-10-25 1997-12-10 美国联合生物医学公司 用于治疗变态反应的合成IgE膜锚肽免疫原
GB9422294D0 (en) * 1994-11-04 1994-12-21 Peptide Therapeutics Ltd Peptides for anti-allergy treatment
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
JPH08333390A (ja) 1995-04-07 1996-12-17 Hoechst Japan Ltd ペプチド及びそれからなる自己免疫疾患治療剤
EP0839155B1 (en) * 1995-07-17 2004-10-13 Medivir UK Ltd CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
KR100584051B1 (ko) 1996-03-01 2006-05-30 노파르티스 아게 알레르기에 대한 백신 접종 및 치료를 위한 펩티드임뮤노겐
JP2000516808A (ja) 1996-08-05 2000-12-19 プレジデント アンド フェローズ オブ ハーバード カレッジ Ｍｈｃ結合ペプチドオリゴマーおよび使用方法
TR199902562T2 (xx) 1997-04-15 2000-02-21 Farmaceutisk Laboratorium Ferring A/S De�i�tirilmi� TNF alfa molek�lleri
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
MXPA00007893A (es) 1998-02-11 2002-10-23 Maxygen Inc Direccion de vectores de vacunas geneticas.
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
IL141868A0 (en) 1998-10-05 2002-03-10 M & E Biotech As Novel methods for therapeutic vaccination
NZ512456A (en) 1998-11-30 2003-10-31 Cytos Biotechnology Ag Ordered molecular presentation of antigens
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
TR200103046T2 (tr) 1999-04-23 2002-06-21 Pharmexa A/S IL5 aktivitesini düşürmek için yöntem.
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
EP1330263A2 (en) 2000-09-06 2003-07-30 Pharmexa A/S Method for down-regulating ige
CN1541266A (zh) 2001-06-15 2004-10-27 唐诚公司 用于治疗过敏症及哮喘病的Fcε融合蛋白

Also Published As

Publication number Publication date
AU2008100A (en) 2000-05-22
EP1135158B1 (en) 2005-12-28
KR100559918B1 (ko) 2006-03-13
PL348611A1 (en) 2002-06-03
JP4205861B2 (ja) 2009-01-07
DE69929240D1 (de) 2006-02-02
EP1135158A2 (en) 2001-09-26
JP2002531064A (ja) 2002-09-24
US7459158B2 (en) 2008-12-02
JP4188353B2 (ja) 2008-11-26
HK1042844A1 (en) 2002-08-30
PT1135158E (pt) 2006-05-31
US20010038843A1 (en) 2001-11-08
WO2000025722A3 (en) 2000-10-12
NO20012135D0 (no) 2001-04-30
ATE314087T1 (de) 2006-01-15
DK1135158T3 (da) 2006-05-15
NO20012135L (no) 2001-06-25
JP2006068015A (ja) 2006-03-16
AU771889B2 (en) 2004-04-08
US6913749B2 (en) 2005-07-05
NZ511079A (en) 2003-08-29
HUP0105392A2 (hu) 2002-04-29
US20040076625A1 (en) 2004-04-22
ES2255325T3 (es) 2006-06-16
WO2000025722A2 (en) 2000-05-11
IL142582A0 (en) 2002-03-10
US20030031663A1 (en) 2003-02-13
KR20010089364A (ko) 2001-10-06
DE69929240T2 (de) 2006-08-31
HUP0105392A3 (en) 2008-04-28

Similar Documents

Publication Publication Date Title
US7459158B2 (en) Immunogenic polypeptides for inducing anti-self IgE responses
RU2711979C2 (ru) Белковый комплекс интерлейкина 15 и его применение
KR101637502B1 (ko) 치료용 개 면역글로불린 및 이를 이용하는 방법
DE69927262T2 (de) Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren
RU2120805C1 (ru) Вакцина, обладающая способностью вызывать иммунный ответ против собственного jge организма, способ получения вакцины и способ иммунизации млекопитающего против опосредуемых jge аллергических реакций
JP2020524000A (ja) 抗ｂｃｍａ重鎖のみ抗体
JPH09502708A (ja) Ｉｌ４により伝達される疾患の治療に有用な組み換え型ｉｌ４抗体
EP0512064B1 (en) Extracellular segments of human ige immunoglobulin anchoring peptides and antibodies specific therefor
RU2162711C2 (ru) Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
JP2002537403A (ja) ＩｇＥのＣ−イプシロン−３またはＣ−イプシロン−４ドメイン由来のエピトープまたはミモトープ、その拮抗薬、及びそれらの治療的使用
US20090169549A1 (en) Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use
CN102343090A (zh) 一种治疗类风湿性关节炎的医药组成物
RU2214279C2 (ru) Усовершенствованные вакцины
AU2672700A (en) Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
EP1123317A1 (en) Immunoglobulin variants
JP7649923B2 (ja) ＧＰＣ３標的化抗体インターフェロンα融合タンパク質及びその使用
EP1621209A2 (en) Vaccines based on domains of chimeric immunoglobulin E peptides
HK1042844B (en) Enhanced vaccines based on chimeric immunoglobulin e peptides
MXPA01004372A (en) Enhanced vaccines
JP2000502995A (ja) Ｂリンパ球による抗体放出を刺激する組成物および方法
CA3258260A1 (en) CD73 ANTIBODY COCKTAIL THERAPY
RO116809B1 (ro) Anticorp recombinant, monoclonal, compozitie farmaceutica si metoda de tratament cu aceasta

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued